Loading clinical trials...
Loading clinical trials...
An Open-Label, Multicenter, Phase 1 Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Intravenous Doses of Inhibrx rhAAT-Fc (INBRX-101) in Adults With Alpha-1 Antitrypsin Deficiency (AATD)
Conditions
Interventions
INBRX-101/rhAAT-Fc
Locations
10
United States
UC Davis School of Medicine
Sacramento, California, United States
University of Florida College of Medicine
Gainesville, Florida, United States
University of Miami
Miami, Florida, United States
Indiana University
Indianapolis, Indiana, United States
Hannibal Clinic
Hannibal, Missouri, United States
The New Zealand Respiratory and Sleep Institute
Auckland, New Zealand
Start Date
July 19, 2019
Primary Completion Date
August 18, 2022
Completion Date
August 18, 2022
Last Updated
September 13, 2022
NCT00500123
NCT02796937
NCT06677307
NCT02900183
NCT06186492
NCT03767829
Lead Sponsor
Inhibrx Biosciences, Inc
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions